Hapabapa/East editorials via Getty Images
Bristol Myers Squibb (Nyse:BMY) announced on Saturday that his inhibitors of control points general and Yervoy, in combination, reduced the risk of disease progression or death by 38% in phase 3 tests for patients with a certain type of colorectal cancer.
Citation
